Lymphoma Roundtable
The panel discusses new targets for DLBCL and FL and shares what excites them about the future for these diseases.
Advertisement
The panel discusses regulatory hurdles and patient access considerations for non-Hodgkin lymphoma therapies.
The panel discusses treatment sequencing after CAR-T or transplant and the role bispecifics and other regimens may play.
The panel discusses combination therapy options for patients with DLBCL and FL.
Advertisement
The panel discusses novel treatment options for FL, including bispecifics, CAR-Ts, monoclonal antibodies, and more.
The panel talks about novel therapies for DLBCL, including the timing and sequencing for such treatments and more.
The panel discusses barriers to improving treatment options for patients with DLBCL and follicular lymphoma.
A panel discusses the unmet needs and emerging therapeutic areas for DLBCL and follicular lymphoma.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.